Oral cancer test gets UK boost:
This article was originally published in Clinica
Zila's UK licensee Stafford-Miller, a division of Block Drug, is launching a marketing campaign for Zila's OraTest oral cancer detection system. The five-minute mouth-rinse for squamous cell carcinoma is known as OraScreen in the UK. Stafford-Miller is aiming the campaign at dentists in general practice. The product is available or approved in Australia, Canada, Taiwan, Hungary, Bermuda and other countries. FDA approval is pending.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.